Several antibody-based PD-1 inhibitors (e.g. Pidilizumab and Nivolumab) and PD-L1 inhibitors (e.g. Atezolizumab and Durvalumab) have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of various cancers (3). The gene discussed is PDCD1; the disease is cancer.